Show summary Hide summary
Oklahoma City has a new player in the effort to scale advanced cell treatments: CytoGrowth Solutions, a venture spun out of Our Blood Institute that turns underused blood components into materials meant to feed and expand therapeutic cells. The move addresses an immediate bottleneck for labs and manufacturers racing to bring cell and gene therapies to patients.
From discarded blood to manufacturing inputs
Cell-based therapies rely on extracting immune cells from donors or patients, reprogramming them, and growing them in controlled labs before infusion. That growth phase depends on specialized nutrients and plasma-derived inputs that are often scarce or single-source—creating a practical limit on how fast new treatments can move from trial to production.
OKC metro sports venues: 5 major projects set to open soon
Tariff refunds sent to businesses: consumers may get little or no relief
CytoGrowth Solutions applies techniques developed at OBI to convert salvage blood components—material that would otherwise be discarded—into standardized, usable products for the cell therapy pipeline. The work is aimed at reducing dependence on rare supplies and expanding the raw-material base for therapeutic manufacturing.
Why this matters now
Demand for cell and gene therapies has surged, but supply of certain blood-derived ingredients has not kept pace. That mismatch risks slowing clinical development and could constrain the commercial scale-up of some promising treatments.
By creating alternatives to limited sources of plasma and platelet-derived supplements, the startup intends to make it easier for manufacturers to produce therapies at scale without waiting for scarce donor types or expired components.
What the new facility will do
The company has opened a manufacturing site in Oklahoma City and plans to produce four distinct products targeted at the cell and gene therapy market. Operations began with a compact team of 12 staffers covering laboratory work, regulatory affairs and production, with hiring expected to grow as output scales.
- Repurposing waste: Salvaged blood components are processed into nutrient formulations.
- Scaling supply: Products are designed to be more widely available than current, limited materials.
- Supporting manufacturing: Intended to ease constraints during cell expansion phases.
- Regulatory focus: Early staffing includes regulatory specialists to help meet quality and compliance needs.
Local ecosystem and broader implications
Leaders in Oklahoma City see the startup as a practical example of research translating into commercial capacity. The operation adds a manufacturing node to a growing bioscience cluster and creates technical jobs tied directly to advanced therapeutics.
For patients and developers, the change could shorten timelines and lower one of several nonclinical barriers to broader access: the availability of consistent, high-quality materials needed to grow therapeutic cells. That’s particularly important for complex treatments that depend on donor-derived inputs that are rare in the general population.
OBI frames the effort as a systems-level fix rather than a single-product play—an attempt to unclog a supply chain problem that could otherwise throttle multiple drug programs if left unaddressed.
What to watch next
Over the coming months observers will be looking for regulatory clearances, product validation data and nascent supply agreements with therapy developers. Those milestones will determine whether this local experiment can meaningfully reshape materials sourcing for an industry currently constrained by availability of certain blood-derived inputs.
If successful, the model could be replicated in other regions, offering a path to broaden the material base for cell and gene therapies while reducing waste and strengthening manufacturing resilience.
